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The measurement of faecal tumour M2 pyruvate kinase (tumour M2 PK) has been proposed as a novel approach for early detection
of colorectal cancer (CRC). However, as regards the potential of the test to detect precursors to CRC, an issue that is highly relevant
to estimate its use in reducing CRC incidence and mortality, the available evidence is scant and controversial. The aim of our study
was to determine the performance characteristics of the tumour M2 PK test with respect to colorectal adenomas in the target
population of screening. Among 1082 participants of screening colonoscopy in Germany, of whom 30% had any adenoma and 10%
had an advanced adenoma, the median (interquartile range) tumour M2 PK level in the whole study population was 1.3Uml
 1 (0.3–
3.3). At a cutoff value of 4Uml
 1, sensitivity was 22 and 23% for detection of advanced and other adenomas, respectively, whereas
specificity was 82%. The area under the receiver-operating characteristics curve (95% confidence interval) was 0.54 (0.51–0.58) and
0.56 (0.52–0.59) for advanced and other adenomas, respectively. In conclusion, the tumour M2 PK test has only very limited
potential to distinguish between people bearing precursors to CRC and people with no finding at colonoscopy.
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The measurement of faecal tumour M2 pyruvate kinase (tumour
M2 PK), an isoform of the glycolytic enzyme PK, which is
overexpressed in proliferating cells such as tumour cells, has been
proposed as a novel approach for early detection of colorectal
cancer (CRC) (Mazurek et al, 2002). Previous studies investigating
this test reported a comparably high sensitivity for CRC ranging
about 70–80%, whereas specificity ranged about 70–90% (Hardt
et al, 2004; Vogel et al, 2005; Shastri et al, 2006; Tonus et al, 2006;
Haug et al, 2007; Mulder et al, 2007; Koss et al, 2008). However, the
potential of the tumour M2 PK test to detect colorectal adenomas,
an issue that is highly relevant for estimating its use in reducing
CRC incidence and mortality, has been investigated rarely and with
rather limited sample size only (Vogel et al, 2005; Shastri et al,
2006; Mulder et al, 2007; Koss et al, 2008). Interpretation of
pertinent findings regarding relevance for screening is further
limited in that previous studies were typically conducted in
subjects referred to colonoscopy because of symptoms or special
risk factors. The aim of our study was to determine performance
characteristics of the tumour M2 PK test with respect to colorectal
adenomas in a large sample of women and men from the target
population of screening.
MATERIALS AND METHODS
The analyses were part of the BliTz study (Begleitende Evaluierung
innovativer Testverfahren zur Darmkrebsfru ¨herkennung), an on-
going screening study conducted in cooperation with 20 gastro-
enterological practises in South-West Germany since January 2006,
which aims at the comparative evaluation of new tests for early
detection of CRC. The study includes participants of screening
colonoscopy, which is offered by the German health-care system
since October 2002 to average-risk subjects aged 55 years or older.
People with visible colorectal bleeding or with insufficient knowl-
edge of the German language were excluded. After written
informed consent, patients scheduled for screening colonoscopy
were asked to provide a stool sample before bowel preparation for
colonoscopy. The stool sample was collected according to the
manufacturer’s instructions with a special stick capturing 4mg of
stool and was sent by mail to a central laboratory. The sampling
date and the date of receipt at the laboratory were documented.
Upon receipt, stool samples were stored at  201C and analysed for
tumour M2 PK within 1 month. After colonoscopy was performed,
reports on colonoscopic and histological findings were collected
and information was extracted in a standardised manner. The
study was approved by the Ethics Committee of the University of
Heidelberg.
Tumour M2 PK was measured with a commercially available
sandwich ELISA (ScheBo
s Biotech AG, Giessen, Germany) based
on monoclonal antibodies against dimeric M2 PK. All analyses
were done in a blinded manner and under standardised
conditions.
For the present analyses, study participants tested for tumour
M2 PK until 10 December 2007 with adequate bowel preparation
and complete colonoscopy (caecum was reached) were included.
We excluded patients with CRC (this subgroup comprised only 10
participants by the end of 2007) as sensitivity with respect to CRC
will be analysed separately after continued recruitment of a much
larger number of screening participants. To account for the limited
stability of tumour M2 PK at room temperature (Haug et al, 2006),
only participants whose stool samples arrived at the laboratory
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swithin 2 days after sampling were included as recommended by the
manufacturer. Using SAS version 9.1, sensitivity, specificity and
predictive values of the test for detecting any adenoma and, more
specifically, advanced adenomas (i.e., adenomas that are at least
1cm in diameter, adenomas with villous components or with high-
grade dysplasia) and other adenomas were calculated at a cutoff
value of 4Uml
 1, the cutoff level proposed by the manufacturer,
and 95% confidence intervals (95% CI) were determined based on
the exact binomial distribution. Nonparametric and w
2 tests were
used to compare medians and proportions, respectively. In
addition, sensitivity and specificity were derived at a broad range
of alternative cutoff values and, receiver-operating characteristic
curves (ROC) were constructed to visualise the discriminatory
power of the test. Area under the curves (AUC) and corresponding
95% CIs were calculated using MedCalc for Windows, version
9.3.9.0.
RESULTS
Overall, 1082 participants (mean age 63 years, 50% females) were
included in the analyses. Although the majority of stool samples
arrived at the laboratory within 1 day, 32% of samples arrived after
2 days only. The median (interquartile range) tumour M2 PK level
in the whole study population was 1.3Uml
 1 (0.3–3.3). Median
tumour M2 PK levels did not differ by gender or duration of
mailing, but tended to be higher in older age groups (P¼0.002)
(see Table 1).
The distribution of findings at colonoscopy, median tumour M2
PK and test performance characteristics at a cutoff level of
4Uml
 1 (recommended by the manufacturer) by subgroup are
shown in Table 2. Overall, about 30% of participants had at least
one adenoma and about 10% of participants had an advanced
adenoma. Sensitivity (95% CI) for advanced adenomas and other
adenomas was 22% (14–31%) and 23% (17–29%), respectively.
There was no significant variation of sensitivity by location,
number or size of adenomas. Sensitivity appeared to be slightly
higher among participants with three or more adenomas, but CIs
were wide given the small number of patients in this group.
Sensitivity did not vary by age, gender or shipping time of stool
samples. The positive predictive value (95% CI) was 34% (28–
41%) for bearing any adenoma and 11% (7–16%) for bearing an
advanced adenoma.
Specificity (95% CI) was about 82% (78–84%), irrespective of
whether participants with hyperplastic polyps were included as
controls or not. Specificity did not vary in gender or shipping time
of stool samples, but tended to be lower in older age groups
(P¼0.001). The negative predictive value was 61% (57–64%)
when including only participants with no polyp as controls and
71% (68–74%) when including participants with hyperplastic or
no polyp as controls.
The AUC (95% CI) was 0.54 (0.51–0.58) for advanced adenomas
and 0.56 (0.52–0.59) for other adenomas (see Figure 1).
DISCUSSION
Our study, which is the largest study so far to investigate the
potential of the tumour M2 PK test to detect colorectal adenomas,
showed a sensitivity for both advanced and other adenomas of
about 22–23%, which was only slightly higher than the false-
Table 1 Distribution of age and sex among study participants and
median tumour M2 PK levels by age
Age group
(years)
No. of
participants
(%) % females
Median tumour M2 PK
level (interquartile range)
(Uml
 1)
30–49 23 (2.1) 52.2 0.8 (0.1–1.4)
50–59 356 (33.1) 53.1 1.0 (0.2–2.6)
60–69 517 (48.0) 51.1 1.4 (0.4–3.4)
70–79 171 (15.9) 43.3 1.8 (0.5–4.1)
80+ 10 (0.9) 10.0 2.0 (1.1–8.7)
Tumour M2 PK¼tumour M2 pyruvate kinase.
Table 2 Distribution of findings at colonoscopy, tumour M2 PK levels and performance characteristics of the tumour M2 PK test at a cutoff level of
4Uml
 1 among participants of the BliTz study
Finding at colonoscopy
a No. of participants (%)
Median tumour M2 PK level
(interquartile range) (Uml
 1)
Sensitivity
(95% CI) (%)
1082 (100.0) 1.3 (0.3–3.3)
Advanced adenomas
b 106 (9.8) 1.6 (0.5–3.7) 21.7 (14.3–30.8)
Other adenomas 216 (20.0) 1.7 (0.5–3.7) 22.7 (17.3–28.9)
Stratified by location of adenomas
c
Proximal 123 (38.2)
d 1.7 (0.6–3.4) 27.8 (16.5–41.6)
Distal 145 (45.0)
d 1.5 (0.5–3.6) 22.1 (15.6–29.7)
Both 54 (16.8)
d 1.7 (0.3–4.3) 20.3 (13.6–28.5)
Stratified by number of adenomas
1 adenoma 207 (64.3)
d 1.5 (0.5–3.4) 19.8 (14.6–25.9)
2 adenomas 76 (23.6)
d 1.8 (0.4–4.0) 23.7 (14.7–34.8)
3 or more adenomas 39 (12.1)
d 1.8 (0.4–5.1) 33.3 (19.1–50.2)
Stratified by size of adenomas (in diameter)
o1cm 254 (79.0)
d 1.5 (0.4–3.6) 22.1 (17.1–27.7)
X1cm 68 (21.0)
d 1.8 (0.6–4.0) 23.5 (14.1–35.4)
Hyperplastic polyp 111 (10.3) 1.0 (0.3–2.8) NA
No polyp 649 (60.0) 1.2 (0.3–3.0) 81.5 (78.3–84.4)
No or hyperplastic polyp 760 (70.2) 1.2 (0.3–3.0) 81.7 (78.8–84.4)
BliTz¼Begleitende Evaluierung innovativer Testverfahren zur Darmkrebsfru ¨herkennung; CI¼confidence interval; NA¼not applicable; tumour M2 PK¼tumour M2 pyruvate
kinase.
aAllocation to subgroups according to the most advanced finding at colonoscopy.
bDefined as adenomas that are at least 1cm in diameter, adenomas with villous
components or with high-grade dysplasia.
cProximal/distal to the splenic flexure.
dPercentage in parentheses refers to participants bearing adenomas, i.e., N¼322 participants.
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spositive rate in the same study population. Thus, despite the AUCs
being slightly but statistically significantly above 0.50, this test
appears to have only very limited potential to distinguish between
people bearing precursors to CRC and people with negative
colonoscopy.
The results of previous studies investigating this issue, which
relied on smaller sample sizes (number of adenomas o50 in all
studies) and study populations typically recruited in clinical
settings, were ambiguous: although two of them were in line with
our findings (Vogel et al, 2005; Shastri et al, 2006), one study
reported a statistically significant difference in positivity rates
between subjects with adenomas and with no findings (Mulder
et al, 2007), whereas another study also reported a difference, but
were unable to allow for meaningful statistical comparison (only
10 subjects with adenomas and 13 controls) (Koss et al, 2008).
The finding that faecal tumour M2 PK levels are not markedly
increased in subjects with colorectal adenomas is in contrast
to the much higher overall sensitivity that has been reported for
invasive CRC, but it is consistent with the stage-dependent
performance of this test observed for CRC: all pertinent
studies reported notably higher sensitivity for more advanced
CRC than for less advanced CRC (Hardt et al, 2004; Tonus et al,
2006; Haug et al, 2007; Mulder et al, 2007; Koss et al, 2008). This
suggests that in the precancerous phase, the critical stage of
neoplasia leading to increased faecal tumour M2 PK levels may not
be reached yet.
In our study, higher tumour M2 PK levels were observed in
older age groups than in younger age groups, which slightly
affected the specificity of the test but not its sensitivity. So far, only
one study has investigated tumour M2 PK levels according to age,
which, however, did not observe such an association (Haug et al,
2007). Further evidence is therefore needed to confirm a potential
age dependency of this marker.
Our study might be limited by the diagnostic accuracy of
colonoscopy regarding the detection of precancerous lesions in
routine practise (Barclay et al, 2006). In particular, 20 different
gastroenterologists were involved in patient recruitment and
colonoscopy. However, high levels of qualification and experience
are a prerequisite for conducting screening colonoscopies in
Germany: only experienced endoscopists (internists/gastroentero-
logists or surgeons with pertinent certified specialisations, having
conducted at least 200 colonoscopies and at least 50 polypectomies
under supervision in the preceding two calendar years) are
permitted to conduct screening colonoscopies. Requirements for
maintenance of permission include conduction of at least 200
colonoscopies and at least 10 polypectomies per year. Conduction
of a study in this very setting should ensure maximum possible
relevance of results under routine screening conditions.
In conclusion, the tumour M2 PK test has only very limited
potential to distinguish between people bearing precursors
to CRC and people with no finding at colonoscopy in the screening
setting.
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Figure 1 Receiver-operating characteristics curve for the tumour M2 PK
stool test in detecting patients with colorectal adenomas.
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